- Conditions
- Influenza
- Interventions
- PanBlok, rHA adjuvant
- Biological
- Lead sponsor
- Protein Sciences Corporation
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Omaha, Nebraska • Rochester, New York • Austin, Texas + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 17,247
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PF-00734200 30 mg QD, PF-00734200 20 mg QD, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Litchfield Park, Arizona + 61 more
- Conditions
- GJB2-mediated Hearing Loss, GJB2 Gene Mutation, DFNB1A
- Interventions
- SKY-GJB2
- Combination Product
- Lead sponsor
- Skylark Bio Inc.
- Industry
- Eligibility
- 9 Months to 7 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Oklahoma City, Oklahoma + 1 more
- Conditions
- Carcinoma, Non-small Cell Lung, Lung Cancer
- Interventions
- Satraplatin
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer, Renal Cell Carcinoma
- Interventions
- IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel, Bevacizumab
- Drug
- Lead sponsor
- Infinity Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 24
- States / cities
- Chandler, Arizona • Tucson, Arizona • Fullerton, California + 20 more
- Conditions
- B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
- Interventions
- Surovatamig
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 19 more
- Conditions
- Melanoma
- Interventions
- PV-10, Pembrolizumab
- Drug
- Lead sponsor
- Provectus Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Lebanon, New Hampshire • Portland, Oregon + 2 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- FID007
- Drug
- Lead sponsor
- Fulgent Pharma LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Tampa, Florida + 3 more
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Interventions
- autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim, methotrexate, thiotepa, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Breast Neoplasms
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Background hormonal therapy
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 11
- States / cities
- Bakersfield, California • La Jolla, California • Aurora, Colorado + 8 more
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Urothelial Cancer
- Interventions
- AVZO-103, Combination Agent
- Drug
- Lead sponsor
- Avenzo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 15
- States / cities
- San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Hypertriglyceridemia
- Interventions
- MAR001, Placebo
- Drug
- Lead sponsor
- Marea Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- TAK-788
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 28 more
- Conditions
- Postoperative Pain
- Interventions
- Bupivacaine HCl, SKY0402
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 7
- States / cities
- Arcadia, California • Laguna Hills, California • Pasadena, California + 3 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- DCR-MYC
- Drug
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • San Antonio, Texas
- Conditions
- Ulcerative Colitis
- Interventions
- UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 2
- States / cities
- Greenville, North Carolina • Salt Lake City, Utah
- Conditions
- Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
- Interventions
- ANG003 Dose A, ANG003 Dose B, Creon
- Drug
- Lead sponsor
- Anagram Therapeutics, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 27
- States / cities
- Long Beach, California • Los Angeles, California • Denver, Colorado + 23 more
- Conditions
- Total Knee Arthroplasty, Osteoarthritis
- Interventions
- DePuy Attune posterior stabilizing fixed bearing knee system
- Device
- Lead sponsor
- The University of Tennessee, Knoxville
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Charlotte, North Carolina • Knoxville, Tennessee
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Interventions
- SB-509, Normal Saline
- Drug · Other
- Lead sponsor
- Sangamo Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 14
- States / cities
- La Jolla, California • Lakewood, California • San Francisco, California + 11 more
- Conditions
- Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
- Interventions
- Toripalimab, Paclitaxel
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Anxiety Generalized
- Interventions
- MM120, Placebo
- Drug · Other
- Lead sponsor
- Definium Therapeutics US, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Irvine, California • La Jolla, California + 18 more
- Conditions
- Prostate Cancer
- Interventions
- fulvestrant
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell, Lung Cancer Non-Small Cell Stage IIIB, Lung Cancer Non-small Cell Stage IV, Lung Cancer, Non-small Cell
- Interventions
- Luveltamab tazevibulin
- Drug
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Lake Mary, Florida + 4 more
- Conditions
- Breast Cancer
- Interventions
- Margetuximab
- Biological
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 6
- States / cities
- San Francisco, California • Stanford, California • Plantation, Florida + 3 more